 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023 Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023 PR Newswire...

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update PR Newswire ROCKVILLE, Md., Nov. 14, 2023 ROCKVILLE, Md...

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH  Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short...

Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Drops By 35.0%

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License...

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference PR Newswire ROCKVILLE, Md., Oct...

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for...

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform PR Newswire ROCKVILLE, Md., Sept. 11, 2023 ROCKVILLE, Md., Sept...

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics Shuttle Pharma's Selective HDAC6 Inhibitor...

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update PR Newswire ROCKVILLE, Md., Aug. 15, 2023 ROCKVILLE, Md., Aug. 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and...

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial PR Newswire ROCKVILLE, Md., Aug. 3, 2023 ROCKVILLE, Md., Aug. 3...

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and is headquartered in Gaithersburg, MD.

Watchers	2,516
52-Wk Low	$0.42
52-Wk High	$3.42

Volume (M)	48,682.00
52-Wk High	$3.42
52-Wk Low	$0.42

SHPH Shuttle Pharmaceuticals Holdings Inc

About

Feed

News

Earnings

Fundamentals